Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ViroPharma and Wyeth have commenced patient dosing in a phase II study of HCV-796, an inhibitor for the treatment of hepatitis C.
Subscribe to our email newsletter
The objectives of this trial are to assess the safety, tolerability, pharmacokinetic profile and antiviral activity of HCV-796. The trial will asses HCV-796 when used in combination with pegylated interferon alfa-2b plus ribavirin compared to the current standard of care. The companies will add an additional dose or doses of HCV-796 to the trial to further elucidate the dose response.
“Following the strength of the phase I data, we have initiated a phase II program to assess the efficacy of the compound as part of a triple therapy combination, and to continue to add to our safety database,” commented Stephen Villano, ViroPharma's vice president of clinical research and development.
Hepatitis C is a blood-borne virus recognized as a major cause of chronic hepatitis worldwide. The World Health Organization estimates that 170 million persons worldwide are infected with hepatitis C, and three to four million persons are newly infected globally each year.